Eylea
ApprovedSmall molecule
BayerEylea is used to treat eye diseases that cause vision loss, particularly age-related macular degeneration and diabetic retinopathy, by reducing abnormal blood vessel growth in the eye.[2] Eylea is currently approved and in use across 6 indications[4].[1]
Eylea is one of 127 small molecule programs targeting Retinopathy of Prematurity. It is currently in Approved.
6
Indications
28
Total Trials
3
Active Trials
126
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Eylea
BayerApproved
Retaane
AAlcon Research
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration8 trials
Show 5 more trials
Diabetic Macular Edema4 trials
Show 1 more trial
Wet Age-Related Macular Degeneration3 trials
Neovascular AMD2 trials
10 more indications
Quality of Life1 trial
Efficacy1 trial
Effectiveness1 trial
Diabetic Macular Oedema1 trial
Efficacy and Safety1 trial
Retinopathy of Prematurity1 trial
Polypoidal choroidal vasculopathy1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eylea drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Eylea. EMBL-EBI & Wellcome Sanger Institute.
- [5]